GlassScriptPhysician profile
Elayne K Garber
NPI 1508960840
$6,210.13
in general payments reported to CMS, 2019-2025
23 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $102 · 2021: $334 · 2022: $1,011 · 2023: $1,233 · 2024: $1,429 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,307 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,306.70 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,474.76 | 2019-2025 | |
| Amgen INC. | $1,043.32 | 2019-2025 | Amjevita, Enbrel, Tavneos |
| Janssen Biotech, INC. | $627.68 | 2019-2025 | Tremfya |
| Ucb, INC. | $474.43 | 2021-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $416.26 | 2021-2025 | Tymlos |
| Pfizer INC. | $367.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $362.19 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $349.69 | 2019-2024 | |
| Lilly USA, LLC | $251.12 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $223.88 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.98 | 2023-2024 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $93.88 | 2022-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $87.62 | 2021-2025 | Lupkynis |
| Cumberland Pharmaceuticals, INC. | $56.70 | 2022 | |
| Genentech USA, INC. | $47.20 | 2024-2025 | Actemra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $47.01 | 2019 | |
| Sobi, INC | $45.04 | 2024 | |
| Horizon Therapeutics Plc | $39.30 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $22.18 | 2021 | |
| Sandoz INC. | $20.44 | 2023 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $19.10 | 2024 | Arcalyst |
| Genzyme Corporation | $15.27 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elayne Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.